Moteur de recherche d’entreprises européennes
Financement de l’UE (7 537 801 €) : Suivi personnalisé de la réponse en oncologie : co-création d’essais cliniques dans le cancer du sein avancé Hor01/01/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Suivi personnalisé de la réponse en oncologie : co-création d’essais cliniques dans le cancer du sein avancé
PREMIO COLLAB’s vision is to prolong overall survival and improve the quality of life for patients with metastatic breast cancer (MBC) by providing refined guidance for managing response monitoring. PREMIO COLLAB strives to facilitate improved patient care and streamlined clinical workflows addressing the needs of patients, healthcare professionals, and society. Response evaluation methods for patients with MBC have not been modernised for decades, although molecular imaging with FDG-PET/CT has emerged as a highly accurate method for staging MBC, and staging and monitoring MBC has a profound influence on treatment options and the chances of survival. Furthermore, the patient perspective has rarely been considered, although continuous response evaluation in a monitoring setting has interacted with the life of MBC patients for years. Still, no specific recommendations are provided internationally for response evaluation in MBC or in the overall management of monitoring. PREMIO COLLAB offers complementary competencies in an interdisciplinary collaborative effort to lift this complex task. In a pragmatic multicenter randomised clinical trial (RCT), we will apply the intervention of FDG-PET/CT-based monitoring and compare it with conventional CT as state-of-the-art. The objectives are to analyse the impact of the intervention on overall survival and quality of life in patients with MBC and include cost-effectiveness analyses directly informing HTA agencies and health policymakers. Building on knowledge from the RCT, we will use participatory research designs to develop improved and modernised patient pathways and digital workflows. AI-based solutions in imaging and liquid biopsies constitute perspectives with a broader horizon. The work will be done in multiple European centres and living labs with patient representatives, clinicians, and relevant stakeholders aiming to provide knowledge for updated recommendations with a view to subsequent clinical implementation. This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics).”
| UNIVERSITE DE GENEVE | ? |
| Aarhus Universitetshospital | 263 000 € |
| Alma Mater Studiorum - Universita Di Bologna | 377 625 € |
| Humanitas Mirasole S.p.A. | 544 750 € |
| Irccs Azienda Ospedaliero- Universitaria Di Bologna | 363 176 € |
| KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM) | 887 000 € |
| Region Hovedstaden | 526 000 € |
| Region Nordjylland (North Denmark Region) | 263 000 € |
| Region Syddanmark | 2 535 375 € |
| Research Consortium FOR Medical Image Analysis | 376 125 € |
| Syddansk Universitet | 932 125 € |
| Umit Tirol - Private Universitat FUR Gesundheitswissenschaften UND Technologie GmbH | 469 625 € |
https://cordis.europa.eu/project/id/101136812
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Universite de Geneve, Genève, Suisse.